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Abstract Effective strategies to combat recent rises in
obesity levels are limited. The accumulation of excess
body fat results when energy intake exceeds that
expended. Energy balance is controlled by hypothalam-
ic responses, but these can be overridden by hedonic/
reward brain systems. This override, combined with un-
precedented availability of cheap, energy-dense, pal-
atable foods, may partly explain the increase in over-
weight and obesity. The complexity of the processes
that regulate feeding behaviour has driven the need
for further fundamental research. Full4Health is an
EU-funded project conceived to advance our under-
standing of hunger and satiety mechanisms. Food in-
take has an impact on and is also affected by the gut-
brain signalling which controls hunger and appetite.
This review describes selected recent research from
Full4Health and how new mechanistic findings could
be exploited to adapt and control our physiological
responses to food, potentially providing an alternative
solution to addressing the global problems related to
positive energy balance.
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Introduction
The last 30 years has seen an unprecedented rise in global
obesity levels; from 1980–2008, worldwide obesity preva-
lence almost doubled [1]. The growing impact of this trend
on health has been profound since obesity is a major risk
factor for most non-communicable disease including cardio-
vascular disease, cancers, chronic respiratory disease and dia-
betes. This inevitably adds further economic burden on al-
ready overstretched healthcare systems [2]. The accumulation
of body fat that underlies obesity is fundamentally a reflection
of positive energy balance, where energy consumed as food
and drink exceeds that expended throughmetabolism, thermo-
genesis and physical activity. Nevertheless, the relative stabil-
ity observed in body weight over extended periods of time for
most individuals highlights the existence of a regulatory sys-
tem of considerable precision given the complexity and pat-
terning of the components that need to be integrated—meals,
snacks and drinks of variable energy and macronutrient com-
position on one side of the equation, and voluntary exercise
and the obligatory components of metabolism on the other.
Clearly, many of these contributors vary significantly within
and between days and over the longer term, and the regulatory
system needs to be able to function effectively in the face of
this temporal heterogeneity.
Although energy balance has a high degree of precision in
its regulation, this regulation is biased in favour of caloric
over-consumption to mitigate the risk of starvation, a neces-
sary evolutionary strategy in the past when food supplies were
scarce or unpredictable—the ‘feast or famine’ scenario [3].
The system is thus very sensitive to negative energy balance
but comparatively tolerant of positive energy balance. Fortu-
nately, famine is now rare in the developed world, where
changes in agriculture, production, storage and food process-
ing over the last century have culminated in the plentiful
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supply of cheap, palatable and nutritious food that we now
take for granted. If appetite and feeding behaviour was simply
controlled by energy requirement, i.e. if energy balance was
the only driver, there would not be an obesity problem. How-
ever, it is now increasingly apparent that the hedonic/reward
brain systems can override the hypothalamic systems that reg-
ulate energy balance and that the variety of energy dense, high
sugar and high fat foods that we are now exposed to is hyper-
stimulating these systems [4]. This scenario can drive food
consumption beyond homeostatic needs, providing a partial
explanation for rises in obesity prevalence, most of which can
be considered to be diet-induced, but also the outcome of
gene-environment interaction [3, 4, 5].
Strategies for Tackling Food Intake and Obesity
Surgical Intervention
It is clear that strategies to combat the growing rise in obesity
prevalence are currently limited in number and efficacy. Con-
sequently, one of the most successful interventions in extreme
obesity is bariatric surgery [6]. However, the associated risk of
complications and mortality, and the potential drain on
healthcare budgets, mean that these procedures are not gener-
ally considered in less extreme cases of overweight or mild
obesity, and it could be argued that this would in any case be
inappropriate. Bariatric surgery includes procedures that act
by either reducing stomach size or capacity or by bypassing
part of the intestine or a combination of the two [7]. Although
the surgical restriction in the size of the stomach was initially
assumed to be a major factor in resultant weight loss, it has
also been shown consistently that a number of procedures
result in sustained changes in blood concentrations of gastro-
intestinal (GI) hormones including those responsible for the
incretin effect; glucagon-like peptide-1 (GLP-1) and gastric
inhibitory peptide (GIP) [6, 7]. These changes in GI hormone
levels are likely to play a role in induction and maintenance of
weight loss. Three main surgical procedures are outlined here.
Adjustable gastric banding creates a smaller stomach pouch
by encircling the stomach with a silicone ring. This purely
restrictive method has no effect on the levels of GLP-1, pep-
tide YY (PYY) and GIP [6]. However, sleeve gastrectomy
(creates a long, thin stomach by longitudinal stapling), which
is also restrictive, increases levels of GLP-1, PYY and GIP
and decreases ghrelin levels. Roux-en-Y-gastric bypass
(RYGB) is a combination of both stomach restriction and
intestinal bypass; a small stomach pouch is created, bypassing
the pylorus and duodenum and taking nutrients directly to the
ileum. Nutrients do not mix with bile and pancreatic juices
until they meet in the newly constructed common limb. In-
creased levels of GLP-1 and PYY, reductions in GIP, and
changes in ghrelin have been consistently observed [6, 7].
Sleeve gastrectomy can result in excess weight loss of
77.5 % BMI at 3 years post-surgery or 53 % BMI at 6 years
post-surgery. RYGB can be similarly effective with excess
weight loss of 59 % BMI less than 2 years post-surgery and
63 % BMI more than 2 years post-surgery [6]. There is also
often rapid resolution of type 2 diabetes post-operatively in
obese patients with prior type 2 diabetes, even before weight is
lost, which can most likely be attributed to the altered GI
hormone levels. The positive outcome of this is long-term
weight maintenance by enhanced glucose regulation and ap-
petite reduction [6, 7].
Pharmacological Therapy
In the last 20 years, elucidation of the neural pathways con-
trolling hunger, appetite and energy homeostasis, and the
feedback of peripheral hormones and metabolites onto these
pathways, has provided numerous potential targets for phar-
macological intervention. Again, the pharmacological thera-
pies have mostly been targeted to individuals with BMI in
excess of 30 for whom their condition is already affecting
health and longevity. Despite this, several drugs which made
it to market were licensed for only a short time before being
withdrawn due to unacceptable side effects [8]. A major rea-
son for limited success in this endeavour is that the gut-brain
systems being targeted are complex, involving many feedback
mechanisms, and with the target signalling molecules often
being distributed in multiple locations. This means that drugs
targeting a particular molecule, such as a receptor, in one
location and with a relevant function, may have unintended
consequences in a different location [4].
This can be illustrated by the example of dexfenfluoramine
which increases the bioavailability of 5-hydroxytryptamine
(5-HT; serotonin), a neurotransmitter involved in a wide range
of functions including energy balance. 5-HT has long been a
target in obesity therapy because increasing its levels reduces
appetite and hence body weight. Dexfenfluoramine increases
availability of 5-HT in all areas, stimulating all 5-HT recep-
tors. Accordingly, significant problems resulted from in-
creased activation of 5-HT in heart valves, leading to
valvulopathy, which together with an increased risk of pulmo-
nary hypertension, resulted in dexfenfluoramine being with-
drawn from the market [9, 10]. Similarly, rimonabant, a can-
nabinoid CB1 receptor antagonist, was licensed for use in
Europe as an anti-obesity therapy due to its effect in reducing
appetite and weight gain. However, it too was subsequently
withdrawn from the market due to serious psychiatric side
effects including anxiety, depression and suicide [4, 9]. For
other potential therapeutics, drug programmes have been
shelved or abandoned before making it to market. For exam-
ple, activation of the melanocortin-4 receptor (MC4R), locat-
ed in the paraventricular nucleus of the hypothalamus, de-
creases food intake and increases energy consumption, mak-
ing it an attractive therapeutic target. Mutations causing
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MC4R dysfunction result in lack of satiety and reduced ener-
gy expenditure leading to severe obesity. However, although a
number of MC4R agonists have demonstrated efficacy in pre-
clinical studies, none have progressed beyond phase I or II
trials due to undesirable side effects in the clinic, including
increased blood pressure and heart rate [11].
Food Reformulation and Behaviour Change
The above discussion illustrates that although there may be
interventions relevant to individuals with BMI of 30 and
above, there is an unmet need for weight management strate-
gies in the wider population where the challenge is to prevent
or at least slow the progression into overweight and obesity.
Most individuals gain weight slowly over periods of years or
decades [3], and we need to find innovative solutions to sup-
port weight control in this group. Food is frequently cited, not
unreasonably, as being a major part of the problem in weight
gain, but an alternative perspective could see the natural prop-
erties of particular foods and food components being
harnessed to interact with our physiology to naturally limit
calorie intake [3]. Can we target components of the satiety
cascade (see below; [12]) to promote weight management
(weight loss, maintenance of weight loss, restrained weight
gain) in the longer term? This approach might not be suffi-
ciently powerful to address preexisting clinical obesity but
could support better weight management for the majority of
overweight or mildly obese. Such a strategywould be likely to
be combined with lifestyle modification, such as exercise [3].
The Satiety Cascade
The satiety cascade (Fig. 1) proposed by Blundell and col-
leagues more than 20 years ago has been described and
embellished subsequently in a number of excellent reviews
(e.g. [12, 13]). It is a conceptual framework which combines
the physiological events controlling appetite with the simulta-
neous behaviours and psychological experiences that are inte-
gral to the eating process [12]. Hunger is a familiar early
‘signal’ or state leading to the initiation of the eating process,
particularly as it relates to meals, whilst the accumulation of
signals arising from the act of eating ultimately results in the
termination of the eating event. The most commonly per-
ceived hunger signals originate in the stomach where electri-
cal (vagus nerve) signals relate the state of emptiness (or full-
ness), reinforced by the secretion of the hormone, ghrelin, and
by metabolic signals such as blood glucose (hypoglycaemia).
Satiation, or intra-meal satiation, is the process leading to
meal termination and determines meal size. The physiological
state at the end of a meal when further eating is inhibited by
‘fullness’ is termed satiety [12]. Satiety, or between-meal sa-
tiety, ends as meal processing and absorptive signals wane and
hunger initiates the next period of eating. Sensory and
cognitive processes guide meal anticipation and learned asso-
ciations with anticipated reward and pleasure, helping to de-
fine overall meal quality and quantity. The stomach and intes-
tines provide post-ingestive information through the physical
signals of stretch/distension as well as osmotic load, providing
feedback related to meal quantity. Medium-term satiety is
metabolically controlled by gut peptide hormones including
GLP-1, cholecystokinin (CCK) and PYY which are released
as digesta pass through the gastrointestinal tract and have
meal-processing roles in addition to their inhibitory effects
on food intake [14]. The post-absorptive phase is when
long-term satiety is controlled by insulin, glucose and amino
acid concentrations in the blood and oxidation of nutrients in
the liver. The brain integrates signals from all the processes
involved in hedonic and homeostatic appetite control, as well
as those concerning sensory and metabolic satiety. It may be
possible through food reformulation to produce foods that not
only suppress appetite but are also desirable to eat, in order to
influence behaviour change and facilitate healthier food
choices.
Current Research Focus—EU Projects
The complexity of the processes involved in feeding behav-
iour and the contribution of caloric over-consumption to the
rising obesity epidemic has driven the need for further re-
search. This has been recognised by the European Union
(EU) which has funded two related multidisciplinary Frame-
work Programme 7 (FP7) projects, Full4Health and SAtiety
INnovation (SATIN). Full4Health (http://www.full4health.
eu/) is investigating the mechanisms controlling hunger and
satiety, whilst SATIN (http://www.satin-satiety.eu/) seeks to
establish the proof of concept of food reformulation to
enhance satiety leading to long-term health benefit.
Full4Health is a multidisciplinary project focusing on the
mechanisms controlling hunger, satiety and feeding behav-
iour, studying the effects of diet, dietary components and food
structure (Fig. 1). It includes studies of the gut and the signal-
ling systems (neural, hormonal andmetabolic) connecting it to
different brain areas. Although not directly an obesity project,
its aim is to provide an evidence base on which to build solu-
tions to address over-consumption as part of the burgeoning
obesity problem. The mechanisms elucidated could equal-
ly be manipulated to address under-consumption of cal-
ories (malnutrition) such as that seen in the elderly or
clinically compromised, for example in cancer cachexia
or following surgery.
A major focus is a human study investigating the effects of
dietary intervention on different age, BMI and gender groups,
to illustrate the anticipated variations in appetite regulation
across the lifespan. Linked to this is the neuropsychology of
food choice and reward and how it relates to appetite regula-
tion. In addition to this and other human intervention studies,
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mechanisms are being investigated using a number of other
approaches including cell-based systems and preclinical
models, employing cutting-edge technologies such as brain
imaging. These techniques are being applied to a number of
areas of interest including (i) studies during early life and the
impact of nutritional and endocrine manipulations on the de-
velopment of metabolic disease in later life, (ii) whether the
physical form of food (liquid or solid) has different effects on
hindbrain processing, and (iii) the role of the vagus nerve in
communicating signals from the stomach to the brain (part of
the ‘gut-brain axis’).
SATIN has several similar themes to Full4Health
and was conceived to address the problem of sustain-
able weight management through dietary solutions
based on functional food products. It is a proof of
concept study with the aim of identifying novel food
structures that can be incorporated into satiety-
enhancing foods which can be tested for their effects
on long-term appetite regulation. This ambition reflects
the regulatory environment in Europe where the Euro-
pean Food Safety Agency (EFSA) is responsible for
overseeing the safety and efficacy of food products
across the EU and the claims that food manufacturers
can make about their products. In the case of satiety
enhancement, the requirements are stringent, and food
intake-related or satiety claims for a food will only be
approved if they also result in sustained beneficial ef-
fects on body weight. The project involves screening
novel food structures to identify and characterise
satiety-enhancing foods, followed by the testing of lead
formulations through satiety and health screens, con-
sumer evaluation and ultimately long-term human vol-
unteer studies. Its aim is to find potential foods which
can accelerate within-meal satiation, prolong between-
meal satiety, and reduce snacking between meals [15,
16], but importantly, deliver these outcomes as part of
a whole diet approach that will be beneficial to long-
term health through positive effects on body weight.
Fig. 1 Hunger and satiety: overview of mechanisms and specific targets.
Selected aspects of the Full4Health project include responses to food
intake across the life course, the impact of early life nutrition on
neuronal development and the effect of exercise on feeding behaviour.
An integrated physiological system—the ‘food-gut-brain axis’—controls
what we choose to eat, when we eat it and the impact on our subsequent
behaviour and thus on body weight. Different foci in this axis, as
discussed in the text, may provide targets for adapting and exploiting
responses to food and could deliver alternative solutions to the problem
of overweight and obesity
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Such benefits may not necessarily be direct, and prod-
ucts with an approved satiety claim may help consumers
to make better food choices, thereby assisting with the
maintenance of healthy weight [15, 16, 17, 18, 19, 20,
21, 22, 23].
Full4Health Research Progress
In this final year of Full4Health, we now report a number of
significant developments and scientific advances in our under-
standing of mechanisms of hunger and satiety and consider
how we might utilise these in the battle against obesity
(Fig. 1).
As discussed previously, bariatric surgery, although very
effective, is generally only deployed in cases of extreme obe-
sity. Full4Health’s Norwegian partner in Trondheim, led by
Duan Chen, is investigating less invasive interventions seek-
ing to achieve similar weight loss and clinical outcomes as
currently available surgery. They have demonstrated that
blocking the gastric vagus nerve input to the brain results in
decreased food consumption in a preclinical model (unpub-
lished). The stomach wall is rich in vagus nerve afferents that
play various physiological roles in communication between
the stomach and the brain (part of the so-called gut-brain axis).
Botox (a toxin which blocks release of the neurotransmitter,
acetylcholine, from nerve terminals) has been used to block
the vagus nerve in preclinical trials in rats. After injecting
Botox into the stomach wall of rats that have become obese
by feeding on a high fat diet, it was found that the treatment
reduced food intake, with resultant reductions in body weight
of 25–30 % over a course of 4 weeks [24]. Botox injection
also enhanced weight loss (up to 25 %) in obese rats that had
previously undergone sleeve gastrectomy surgery [24]. These
promising results suggest that this simple treatment has the
potential to be refined into a new less invasive therapy for
obesity. The vagus nerve is also involved in the control of
gastric emptying, but the Trondheim group has found that
Botox injection did not delay gastric emptying and did not
cause any pathological changes in the stomach [24]. There is
a precedent for the use of Botox injection in the clinic—in the
treatment of patients with achalasia, a condition where the
lower oesophageal sphincter remains closed due to failure of
the smooth muscle to relax. So, the technology already exists
for Botox to be easily injected through gastroscopy, with the
whole procedure requiring the patient to stay in hospital for
only a few hours. The promising results generated by Profes-
sor Chen’s group have led to initiation of a Phase II clinical
trial at St. Olav’s Hospital, Trondheim, Norway. Obese pa-
tients have been recruited, and the trial is ongoing. The hope
is that this simple procedure can become an effective method
for treating obese patients with little risk and significantly
lower cost in comparison to obesity surgeries currently used.
It is well-documented that there are strong associations
between early life environment and the risk of developing
metabolic disease, including obesity and diabetes, in later life
[2]. Full4Health partner at the University of Lille, led by
Sebastien Bouret, is investigating early life effects of the stom-
ach hormone, ghrelin. Foetal nutrition was first recognised to
affect long-term metabolic health following study of individ-
uals born in the Dutch HungerWinter at the end of the Second
World War [25]. The sudden onset of the famine and its short
duration of only 5 months provided a remarkable opportunity
to compare its effects with the periods before and after it.
Studies showed that women exposed to the famine during
early pregnancy gave birth to normal weight babies. However,
these offspring had a higher incidence of obesity in later life
than those born before or after the famine and also than those
lower birth weight babies who were exposed to the famine in
mid-late gestation [25]. The lower birth weight babies main-
tained their lower weight throughout life and had lower obe-
sity rates. Although the observations made from this study
form the basis of key information on foetal programming, it
is clear that preclinical studies are necessary to dissect out the
processes and key factors in operation, generating knowledge
that cannot be gleaned from ‘natural experiments’ in man.
Bouret’s group in Lille has inhibited ghrelin action during
the early postnatal period in mice and revealed an important
role for this hormone in the development of hypothalamic
neural circuits; ghrelin blockade enhanced arcuate nucleus
neural projections. They also showed that increasing ghrelin
levels during the postnatal period, and disrupting the normal
development of arcuate nucleus neural projections, resulted in
lifelong metabolic disturbances that were apparent in older
mice, including increases in body weight, higher circulating
leptin and insulin levels and increased glycaemia [26••]. This
is an important development in our understanding of the di-
verse roles of gut-brain peptide hormones, juxtaposing ghrelin
with the adipose tissue hormone, leptin, which is a stimulant
of neurite growth—thus inhibition of the action of leptin sim-
ilarly inhibits neural development [27]. It has been known for
some time that leptin, whilst having a key role in energy bal-
ance and signalling of body fat stores in post-weaning life in
the rodent, also has a neurodevelopmental role during neona-
tal life, as exemplified by the so-called ‘leptin surge’. The
mechanistic studies conducted as part of Full4Health have
added an additional level of complexity to our understanding
of the regulatory processes through which the mapping of the
developing hypothalamic circuitry is determined, with poten-
tial consequences for lifelong health. The Lille group has also
shown that overnutrition by litter size manipulation during the
early postnatal period reduces ghrelin levels, leading to meta-
bolic effects which could not be reversed by injecting ghrelin.
This disturbance of the ghrelin system, which may manifest
itself as ‘resistance’, may be important in explaining the met-
abolic defects in postnatally overnourished mice [28].
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The knowledge that leptin and ghrelin may have counter-
regulatory actions during the postnatal period and combine to
shape the correct development of brain feeding circuits is an
important advance. This will be valuable in designing inter-
ventions, perhaps applicable to maternal/postnatal nutrition in
humans, to address metabolic disease, including the rising
obesity problem.
The enteroendocrine system distributed along the intestinal
tract secretes a number of regulatory peptides with satiety
properties. The mechanisms underlying the beneficial effects
of bariatric surgery in countering both diabetes and obesity
remain to be fully elucidated but are believed to reflect, at least
in part, the activity of nutrient-released gastrointestinal and
pancreatic peptides. Harnessing the potential of this secretory
capability is a strategy being pursued within the Full4Health
project, with the broad aim of mimicking bariatric surgery
through nutrient targeting. GLP-1 is produced by L cells in
the distal ileum, stimulated by ingested nutrients. Ingested
protein stimulates the release of GLP-1, and it is also
established that individual amino acids, such as glutamine
when administered orally, can elevate levels of GLP-1 in lean,
obese and type 2 diabetic individuals [29, 30]. Full4Health
researchers at the University of Cambridge found that
oligopeptides triggered release of GLP-1 via two signalling
pathways in L cells in vitro. The components of these path-
ways are highly expressed and are relatively specific for L
cells, suggesting that they may provide a route to increasing
endogenous GLP-1 secretion, with all the expected benefits
which may result [31••]. This work has been used to inform
research using a preclinical perfused isolated intestine model
elsewhere in the Full4Health consortium [32]. Such synergis-
tic activity illustrates clearly how fundamental mechanistic
studies on GI hormones may provide a novel way to harness
their satiety-enhancing activity and deliver solutions to the
challenge of escalating obesity levels.
Full4Health has grown the evidence base of mechanisms of
satiety and feeding behaviour, whichmay in the future provide
support for the majority of the population who are overweight,
and thereby slow the progression to obesity. However, poten-
tial mechanism-based interventions are most likely to deliver
success if combined with lifestyle modification, such as exer-
cise. The University of Leeds is a Full4Health partner inves-
tigating the effects of exercise on appetite behaviour. Previous
studies had supported the idea that exercise produces less
weight loss than anticipated and that there are gender differ-
ences, with females losing less weight than males [33, 34].
However, it is important for such studies to quantify energy
intake and expenditure. Graham Finlayson and colleagues in
Leeds measured energy expenditure during supervised exer-
cise, comparing changes in body composition in studies of
males and premenopausal females. They found no effect of
gender on changes in body fat content during the supervised
exercise programme [35]. They also noted that the exercise
schedule increased fasting hunger but that this did not result in
higher food intake. A suggested explanation is that even
though hunger was increased, postprandial satiety also in-
creased [36]. This may be explained by suggestions that
long-term exercise increases the levels of the satiety hor-
mones, GLP-1 and PYY [35].
SATIN Research Progress
Progress in this project is discussed in another article, also in
this issue.
Conclusion
Strategies to deal with the rise of obesity have had mixed re-
sults. Bariatric surgery is the most successful of currently avail-
able interventions but is only really applicable to the more
extreme clinical cases. Pharmacological therapy has been beset
by problems of adverse reaction. A larger proportion of the
population are overweight rather than obese, but many are
tracking towards obesity, due to incremental increases in
weight over many years.We need solutions to stem this gradual
upward trajectory at as early a stage as possible. It is accepted
that calorie restriction in the form of dieting generally delivers
rather limited success in weight management, an outcome
which probably reflects the fact that this strategy is being coun-
tered by the body’s natural physiological response to negative
energy balance. Extensive research efforts over the last 30 or so
years have, however, revealed much of the molecular and neu-
roanatomical detail of the control of energy balance, involving
the GI tract, gut peptides, peripheral nerves, and neuroendo-
crine and reward systems in the brain, and how food interacts
with these systems and processes. Perhaps it is now time for a
new approach to try to address the problems of over- and also
under-consumption of calories by using the natural properties
of food, such as differential induction of satiation and satiety, to
enable individuals to control hunger (the biggest reason for
dietary failure) and make better food choices. Full4Health has
delivered mechanistic information regarding hunger and satiety
to inform this process and SATIN is taking this to the next step
by testing the concept of ‘designer’ foods which aim to change
the way we eat. It should be borne in mind however that this
approach will be most likely to yield success when combined
with lifestyle modifications such as exercise.
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